United Therapeutics Corp (UTHR.O)

UTHR.O on Nasdaq

169.76USD
5 May 2015
Change (% chg)

$0.24 (+0.14%)
Prev Close
$169.52
Open
$169.70
Day's High
$171.45
Day's Low
$168.60
Volume
663,387
Avg. Vol
688,965
52-wk High
$190.29
52-wk Low
$84.63

UTHR.O

Chart for UTHR.O

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of unique products to address the unmet medical needs of patients. The Company’s therapeutic products and product candidates include: Prostacyclin Analogues, the lead product is Remodulin Injection, for the... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $7,618.71
Shares Outstanding(Mil.): 46.26
Dividend: --
Yield (%): --

Financials

  UTHR.O Industry Sector
P/E (TTM): 48.78 188.47 40.23
EPS (TTM): 3.38 -- --
ROI: 13.75 -0.64 15.26
ROE: 15.05 -2.50 16.08
Search Stocks

FDA approves United Therapeutics' drug for treating cancer in children

- The Food and Drug Administration said it approved United Therapeutics Corp's drug to treat neuroblastoma, a rare cancer that typically occurs in children below 5 years.

10 Mar 2015

UPDATE 2-FDA approves United Therapeutics' drug for children's cancer

* Analyst expects drug to cost $150,000 per patient per year (Adds analyst comment, background)

10 Mar 2015

FDA approves United Therapeutics' drug for treating cancer in children

March 10 - The U.S. Food and Drug Administration said it had approved United Therapeutics Corp's drug to treat neuroblastoma, a rare form of cancer that most often occurs in young children.

10 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks